PMID- 10068849
OWN - NLM
STAT- MEDLINE
DCOM- 19990420
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 22
IP  - 2
DP  - 1999 Feb
TI  - Differential hormonal profiles of adrenomedullin and proadrenomedullin N-terminal 
      20 peptide in patients with heart failure and effect of treatment on their plasma 
      levels.
PG  - 113-7
AB  - BACKGROUND: Adrenomedullin (AM) is a potent vasodilatory peptide discovered in 
      human pheochromocytoma tissue. Proadrenomedullin N-terminal 20 peptide (PAMP) 
      processed from an AM precursor is also a novel hypotensive peptide which inhibits 
      catecholamine secretion from sympathetic nerve endings. HYPOTHESIS: The present 
      study sought to examine the relationships between the two peptides and other 
      clinical parameters by measuring the plasma AM and PAMP concentrations in 98 
      patients with heart failure. METHODS: In all, 98 patients [65 men and 33 women, 
      aged 58.2 +/- 11.0 years, mean +/- standard deviation (SD)] with heart failure 
      and 26 healthy volunteers (12 men and 14 women, aged 54.1 +/- 8.6 years) were 
      examined in this study. Heart failure was secondary to previous myocardial 
      infarction in 58 patients, valvular disease in 28, cardiomyopathy in 9, and 
      congenital heart disease in 3. All patients were classified into two groups of 
      class I or II (Group 1) and class III or IV (Group 2) according to the New York 
      Heart Association (NYHA) functional classification. RESULTS: Both plasma AM and 
      PAMP concentrations in the patients were significantly higher than those in 
      healthy volunteers. In addition, plasma AM and PAMP concentrations in patients in 
      class III or IV of New York Heart Association (NYHA) classification were 
      significantly higher than those in NYHA class I or II. The elevated plasma 
      concentrations of these peptides in patients in NYHA class III or IV 
      significantly decreased in response to the treatment for 7 days. There was a 
      significant correlation between plasma AM and PAMP, though the plasma 
      concentration of PAMP was one-fifth to one-seventh of that of AM in patients and 
      controls. The plasma AM concentration correlated significantly with the plasma 
      concentrations of atrial and brain natriuretic peptides, epinephrine, and right 
      atrial pressure, whereas such a relationship was not noted for the plasma PAMP 
      concentration. CONCLUSIONS: Judging from the difference in not only the 
      biological actions but also the hormonal profiles between AM and PAMP, they may 
      differentially modulate the cardiovascular system in patients with heart failure, 
      although they are processed from the same precursor.
FAU - Etoh, T
AU  - Etoh T
AD  - First Department of Internal Medicine, Miyazaki Medical College, Japan.
FAU - Kato, J
AU  - Kato J
FAU - Takenaga, M
AU  - Takenaga M
FAU - Imamura, T
AU  - Imamura T
FAU - Kitamura, K
AU  - Kitamura K
FAU - Koiwaya, Y
AU  - Koiwaya Y
FAU - Eto, T
AU  - Eto T
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 0 (Proteins)
RN  - 0 (Vasodilator Agents)
RN  - 0 (proadrenomedullin (9-20))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 148498-78-6 (Adrenomedullin)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adrenomedullin
MH  - Atrial Natriuretic Factor/blood
MH  - Cardiac Catheterization
MH  - Cardiomyopathies/complications
MH  - Epinephrine/blood
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*blood/*drug therapy/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/*metabolism
MH  - Peptides/*blood
MH  - Prognosis
MH  - Proteins/*metabolism
MH  - Radioimmunoassay
MH  - Vasodilator Agents/*blood
PMC - PMC6655257
EDAT- 1999/03/09 00:00
MHDA- 1999/03/09 00:01
PMCR- 2009/02/03
CRDT- 1999/03/09 00:00
PHST- 1999/03/09 00:00 [pubmed]
PHST- 1999/03/09 00:01 [medline]
PHST- 1999/03/09 00:00 [entrez]
PHST- 2009/02/03 00:00 [pmc-release]
AID - CLC4960220211 [pii]
AID - 10.1002/clc.4960220211 [doi]
PST - ppublish
SO  - Clin Cardiol. 1999 Feb;22(2):113-7. doi: 10.1002/clc.4960220211.